Connect with us

IT Industry

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

GlobeNewswire

Published

on

Reading Time: 3 minutes

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”).

Following iBio’s successful use of its technologies and manufacturing capabilities to advance the development of AzarGen’s surfactant protein therapeutic through an initial assessment of production feasibility, in May 2017, the two companies expanded their collaboration by initiating the development of a plant-made rituximab for the South African market under the MOU.

Pursuant to the SOW1, iBio will manufacture research quantities of a plant-made rituximab for AzarGen using iBio’s proprietary FastPharming™ System. Following batch production, the drug product candidate will undergo testing via iBio CDMO’s bioanalytical services.

“After demonstrating the success of our platform through our opening project with AzarGen, we are now advancing to the next stage of the two companies’ collaboration,” commented Robert B. Kay, iBio’s Chairman and CEO. “We look forward to helping AzarGen develop a plant-based, bio-similar rituximab product for the South African market.”

“The early success in combining iBio’s and AzarGen’s advanced genetic engineering and synthetic biology techniques in plants really empowered us to evolve our business plans and product priorities to initiate development of a biosimilar version of rituximab,” said Dr. Mauritz Venter, CEO of AzarGen. “As we continue to move toward the initiation of advanced pre-clinical activities, we are confident that iBio CDMO is ideally suited to provide us with the requisite long-term process development and cGMP manufacturing support. We are excited to take this important step forward in advancing this program. Focusing on accessibility and affordability of biological medicine for the African continent, we look forward to initiating additional projects with iBio as we progress.”

Rituximab was first approved by the U.S. Food and Drug Administration in 1997 for treatment of certain B cell non-Hodgkin lymphomas. Since that time, its clinical uses have expanded to encompass treatment of chronic lymphocytic leukemia, as well as a range of autoimmune diseases, including certain types of rheumatoid arthritis. Rituximab has been placed on the World Health Organization’s List of Essential Medicines and it was ranked as one of the world’s top-10 selling pharmaceuticals in 2018.

About AzarGen Biotechnologies (Pty) Ltd  

AzarGen is a biotechnology company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants. The company’s lead therapeutic candidates are: a biosimilar version of an anti-cancer monoclonal antibody and a recombinant human surfactant protein targeted for various respiratory disease conditions. AzarGen has developed proprietary synthetic DNA promoters for various expression platform applications in plant-made pharmaceuticals, synthetic biology and GM-crop improvement. The AzarGen management team is supported by an experienced advisory board for strategic guidance and intellectual property management. Based in Stellenbosch, South Africa, AzarGen is supported by South Africa’s Industrial Development Corporation (IDC). Further information is available at www.azargen.com.

About iBio

iBio is a global leader in plant-based biopharmaceutical contract development and cGMP manufacturing services.  Our wholly-owned subsidiary, iBio CDMO LLC, uses the FastPharming™ System – which combines plant protein expression, automated hydroponics, and glycan engineering technologies – to rapidly deliver gram quantities of high-quality biologics for research or further manufacturing uses from its 120,000 square foot facility in Bryan, Texas. In addition to contract manufacturing, iBio also offers process development, bioanalytical, and fill-finish services, along with Factory Solutions for the design and build of facilities for plant-made monoclonal antibodies, vaccines, bioinks and more. iBio also uses its advanced manufacturing capabilities in the development of its own therapeutic pipeline, including its lead asset, IBIO-100 (formerly CFB-03) for the treatment of fibrotic diseases. For more information, visit www.ibioinc.com.  

FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY’S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY’S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY’S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

IT Industry

Entelligent, Societe Generale Partner to Offer First-of-its-Kind Climate Change Investment Product

GlobeNewswire

Published

on

Reading Time: 2 minutes

The partnership centers on Entelligent’s proprietary, predictive modeling system to mitigate climate risk resulting in a fixed income annuity offered by one of Europe’s largest financial institutions

BOULDER, Colo., Oct. 17, 2019 (GLOBE NEWSWIRE) — Entelligent, a Colorado technology company focused on climate change, announced today a first-of-its-kind partnership to create a unique, custom investment solution, using Entelligent’s Smart Climate® “E-Score.” 

Entelligent believes asset managers need options beyond divestment to better manage portfolios against the backdrop of the growing systemic risk posed by climate change. Entelligent’s adaptive intellectual property allows investment managers and owners to direct their capital toward companies that are addressing climate risk by increasing investments in energy efficiency, thus reducing their environmental impact. An examination of Entelligent’s IP has been successfully completed by the U.S. Patent Office and a patent will be awarded shortly.

Entelligent’s Smart Climate approach assists investors in managing their exposure to climate change risk, from regulatory efforts to mitigate carbon emissions to the physical effects of climate change and the transition to new energy technologies. The model has been developed since 2012 by Entelligent’s industry experts, climate scientists, and financial professionals, using investment signals to help asset managers construct more risk-resilient portfolios and direct investments toward greater carbon emission reductions as the world moves away from fossil fuels.

Societe Generale, one of the leading European financial services groups, is the first major financial institution to market a product that incorporates Entelligent’s proprietary, predictive climate model in an effort to improve financial performance. Societe Generale is a founding signatory of the Principles for Responsible Banking, and has committed to reducing its exposure to the thermal coal sector to zero by 2040.

The partnership was borne out of discussions with Societe Generale’s Head of Sustainable Investment Solutions for Global Markets, Isabelle Millat. The product, a fixed income annuity for the insurance industry, is part of its multi-product platform focusing on delivering high quality investment and risk management solutions to asset managers, pension funds, private banks, banks, insurance companies, hedge funds, family offices and sovereign funds and retail network distributors around the world.

Entelligent’s Smart Climate’s E-Scores technology met Societe Generale’s stringent requirements, yielding data not only on resilience to climate risk but also on the financial alpha of its ESG products.

“This is a moment where the engine of capitalism is essential to addressing climate change – the existential crisis of our time,” says Thomas H. Stoner, Jr., CEO of Entelligent.  

In July, Entelligent announced agreements with S-Network, a NYC-based leading ESG indexing company, and FactSet, an international open financial data and software solutions company. These strategic distribution partnerships will allow Entelligent to accelerate the commercialization of the Smart Climate E-Scores.

Entelligent has contemporarily launched a Series A equity raise to fund its next phase of growth and provide the market with an alternative and independent data source in the exploding domain of ESG data, especially related to climate change risk.

About Entelligent
Entelligent’s Smart Climate® Data and Analytics are a “top down” climate scenario analytics platform of formulas, systems and indices that assess the climate risk of an investment portfolio and provide critical analytics at the individual security level. Our Smart Climate Solutions can assist asset managers and owners in evaluating portfolio performance by relating both risk and return to a series of critical environmental metrics.

Contact:
Entelligent 
Laurie Greenwood 
lgreenwood@entelligent.com
(303) 443-9447

Continue Reading

IT Industry

Parker to Webcast Annual Meeting of Shareholders on October 23, 2019 at 9:00 a.m. Eastern Time

GlobeNewswire

Published

on

Reading Time: 1 minute

CLEVELAND, Oct. 17, 2019 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that it will webcast its Annual Meeting of Shareholders, which is scheduled for Wednesday, October 23, 2019, beginning at 9:00 a.m. Eastern time.  The live webcast of the annual meeting will be accessible on Parker’s investor information website at www.phstock.com and will be archived on the site for one year.

Parker Hannifin is a Fortune 250 global leader in motion and control technologies.  For more than 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets.  Parker has increased its annual dividend per share paid to shareholders for 63 consecutive fiscal years, among the top five longest-running dividend-increase records in the S&P 500 index.  Learn more at www.parker.com or @parkerhannifin.

###

CONTACT: Contact:
Media –
Aidan Gormley, Director, Global Communications and Branding
216/896-3258
aidan.gormley@parker.com

Financial Analysts –
Robin J. Davenport, Vice President, Corporate Finance
216/896-2265
rjdavenport@parker.com
Continue Reading

IT Industry

Data Storage Corporation Issues Statement About Promotional Activity Concerning Its Common Stock

GlobeNewswire

Published

on

Reading Time: 4 minutes

MELVILLE, N.Y., Oct. 17, 2019 (GLOBE NEWSWIRE) — Data Storage Corporation (OTCQB: DTST) (“DSC” and the “Company”), a provider of diverse business continuity, disaster recovery protection and cloud solutions, announces that it has been notified by OTC Markets Group Inc. (“OTC Markets”) about recent trading and promotional activity concerning the Company’s common stock. 

On October 15, 2019, OTC Markets informed the Company that (i) it became aware of certain promotional activities concerning Data Storage Corporation and its common stock, including the distribution of promotional newsletter emails by unaffiliated third-party sources, including, BeatPennyStocks.com, owned and operated by Stellar Media Group, LLC, and MakePennyStocksGreatAgain.com, owned and operated by Link Media, encouraging investors to purchase the Company’s common stock and (ii) that this promotional activity has had an effect on trading activity and the market for the Company’s securities. The Company understands this promotional activity coincided with higher than average trading volume and fluctuations in the Company’s stock price. The Company was unaware of the promotional activity until informed by OTC Markets, and is unaware of the full nature of the promotional activity, the extent of the dissemination, or the responsible parties.  The Company is not affiliated in any way with the authors of the promotional materials identified by OTC Markets.

The Company has reviewed the statements in the promotional materials provided by the Issuer Compliance of the OTC Markets.  While it appears that certain statements and claims made in the promotional materials were factually correct as they were taken from the Company’s website, historical press releases and other public documents, the Company has determined that certain statements included in these promotional materials related to the Company and its business might be read as false and/or misleading and readers should not place undue reliance on these promotional materials.

In addition, the Company understands that there are statements made in the promotional materials which may be deemed to encourage investors to purchase the common stock of the Company.  Such statements only express the view of the authors. The Company disclaims any potentially exaggerated or misleading statements contained in the promotional materials.

Readers of the promotional materials should not place undue reliance on the promotional materials. Specifically, the Company does not condone the use of sensational language to describe the Company’s business prospects or the growth potential of the Company’s industry.

The Company encourages investors to review the business of the Company on its own merits. The Company does not condone any statements made regarding the urgency of investing in the Company’s common shares or any other similar statements. The Company notes that investing in the Company’s securities involves certain risks and uncertainties which investors should review prior to making any investment decision. The Company directs potential investors to rely solely on its filings and disclosures made with the U.S. Securities and Exchange Commission, available at www.sec.gov.

The Company has made inquiries of its executive officers, directors, controlling shareholders (i.e., shareholders owning 10% or more of the Company’s securities) and the third-party service provider regarding the promotional activities concerning the Company. Neither the Company, nor its executive officers, directors nor, to the Company’s knowledge, its controlling shareholders nor the third party service provider, were involved in any way with the creation or distribution of the promotional materials identified by OTC Markets.  Additionally, neither the Company’s executive officers, directors nor, to the knowledge of the Company, any controlling shareholders or any third-party service providers, sold or purchased shares of common stock of the Company within the last 90 days. 

Charles Piluso, the Company’s CEO, stated, “We continue to execute on our business model and remain extremely encouraged by the outlook for the business.  While some of the information stated in these promotional materials, as it relates to DSC, does represent the core of our business solutions and the marketplace, we do not stand behind any future growth rates stated in the promotional materials, nor do such statements represent any guidance from DSC. Further, the Company is not involved in Artificial Intelligence or Virtual Reality, as stated in the promotional materials, but remains focused on our core solutions.  Nevertheless, we strongly advise the public to continue to rely only on our press releases and filings with the Securities and Exchange Commission for any material information regarding the Company.”

The Company’s investor relations firm engaged since April 1, 2019 is Crescendo Communications, LLC (“Crescendo”).  Prior to Crescendo, the Company engaged Andrew Barwicki Incorporated (“Barwicki”) from January 18, 2017 to March 31, 2019.  Crescendo and Barwicki deny any prior knowledge of or involvement in the creation or distribution of the promotional materials. The Company has not engaged any third parties to provide investor relations services, public relations services or other related services since January 1, 2017 other than the above-mentioned firms.

The Company has not issued any shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.

About Data Storage Corporation

The Company provides a highly secure, enterprise level cloud for IBM i Power systems and Windows, assisting companies in the migration process, while reducing capex and providing flexibility for seasonality with on-demand compute power. Clients have access to an array of solutions: Infrastructure as a Service, disaster recovery, voice and data, security, and email compliance & data analytics. The Company provides solutions to business, government, education and healthcare industries.

For more information, please visit http://www.DataStorageCorp.com.

Safe Harbor Provision

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created thereby.  All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the Company’s future financial position, business strategy, plans and objectives, are forward-looking statements.  Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or expressions.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements.  Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct.  Important factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, those factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 and its other filings and submissions with the SEC.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.  Except as required by law, the Company assumes no obligation to update or revise any forward-looking statements.

Contact:
Crescendo Communications, LLC
212-671-1020
DTST@crescendo-ir.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off